Symbols / EWTX
EWTX Chart
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.07B |
| Enterprise Value | 2.55B | Income | -167.80M | Sales | — |
| Book/sh | 4.92 | Cash/sh | 4.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 146 | IPO | — |
| P/E | — | Forward P/E | -12.39 | PEG | — |
| P/S | — | P/B | 5.83 | P/C | — |
| EV/EBITDA | -13.46 | EV/Sales | — | Quick Ratio | 19.37 |
| Current Ratio | 19.85 | Debt/Eq | 0.76 | LT Debt/Eq | — |
| EPS (ttm) | -1.63 | EPS next Y | -2.31 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -23.02% |
| ROE | -34.19% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 107.27M |
| Shs Float | 67.60M | Short Float | 10.51% | Short Ratio | 8.61 |
| Short Interest | — | 52W High | 31.82 | 52W Low | 10.60 |
| Beta | 0.27 | Avg Volume | 1.34M | Volume | 1.14M |
| Target Price | $40.17 | Recom | Buy | Prev Close | $27.82 |
| Price | $28.66 | Change | 3.02% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$40.17
Mean price target
2. Current target
$29.62
Latest analyst target
3. DCF / Fair value
$-14.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$29.62
Low
$20.00
High
$51.00
Mean
$40.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-27 | main | Evercore ISI Group | Outperform → Outperform | $45 |
| 2025-11-14 | main | JP Morgan | Overweight → Overweight | $34 |
| 2025-11-07 | main | RBC Capital | Outperform → Outperform | $50 |
| 2025-11-07 | main | Wedbush | Outperform → Outperform | $32 |
| 2025-09-25 | init | Goldman Sachs | — → Neutral | $20 |
| 2025-08-19 | main | JP Morgan | Overweight → Overweight | $30 |
| 2025-08-08 | main | RBC Capital | Outperform → Outperform | $49 |
| 2025-06-30 | init | HC Wainwright & Co. | — → Buy | $42 |
| 2025-06-05 | reit | RBC Capital | Outperform → Outperform | $48 |
| 2025-05-16 | main | JP Morgan | Overweight → Overweight | $40 |
| 2025-05-09 | main | RBC Capital | Outperform → Outperform | $48 |
| 2025-04-21 | main | Wedbush | Outperform → Outperform | $43 |
| 2025-04-03 | main | RBC Capital | Outperform → Outperform | $52 |
| 2025-04-03 | down | Scotiabank | Sector Outperform → Sector Perform | $14 |
| 2025-04-02 | main | Piper Sandler | Overweight → Overweight | $51 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $50 |
| 2025-03-04 | reit | RBC Capital | Outperform → Outperform | $56 |
| 2025-01-22 | init | Stifel | — → Hold | $30 |
| 2024-12-17 | main | Evercore ISI Group | Outperform → Outperform | $50 |
| 2024-11-27 | main | Truist Securities | Buy → Buy | $50 |
- Experimental Becker dystrophy drug shows stable function over 3.5 years - Stock Titan ue, 10 Mar 2026 11
- Truist reiterates Edgewise Therapeutics stock rating on trial data - Investing.com ue, 10 Mar 2026 13
- Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily Sat, 07 Mar 2026 16
- Edgewise Therapeutics (NASDAQ:EWTX) Stock Rating Upgraded by HC Wainwright - MarketBeat Sat, 28 Feb 2026 11
- Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance hu, 26 Feb 2026 08
- Edgewise Therapeutics (EWTX) Is Down 6.8% After Wider 2025 Losses And New BMD Data Plans – Has The Bull Case Changed? - simplywall.st Wed, 04 Mar 2026 04
- Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside - DirectorsTalk Interviews ue, 17 Feb 2026 14
- Edgewise Therapeutics (EWTX) Is Down 6.8% After Wider 2025 Losses And New BMD Data Plans – Has The Bull Case Changed? - Sahm ue, 03 Mar 2026 08
- $EWTX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative hu, 30 Oct 2025 07
- Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛 Fri, 06 Mar 2026 14
- Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions - TipRanks Fri, 06 Mar 2026 16
- Three new Edgewise hires get options to buy 51,000 shares - Stock Titan Mon, 02 Mar 2026 14
- FY2026 Earnings Forecast for EWTX Issued By HC Wainwright - MarketBeat Mon, 02 Mar 2026 06
- How Edgewise Therapeutics Inc. (EWTX) Affects Rotational Strategy Timing - Stock Traders Daily ue, 24 Feb 2026 15
- Edgewise Therapeutics (EWTX): Assessing Valuation Following Recent Share Price Volatility - Yahoo Finance Sun, 09 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 115471 | 3399466.0 | — | Sale at price 29.44 per share. | EDRIS BADREDDIN | Director | — | 2026-01-21 00:00:00 | D |
| 1 | 115471 | 170264.0 | — | Conversion of Exercise of derivative security at price 0.39 - 1.93 per share. | EDRIS BADREDDIN | Director | — | 2026-01-21 00:00:00 | D |
| 2 | 473 | — | — | Stock Award(Grant) at price 0.00 per share. | FOX JONATHAN C | Director | — | 2026-01-02 00:00:00 | D |
| 3 | 100000 | 2112450.0 | — | Sale at price 21.12 per share. | RUSSELL ALAN J | Officer and Director | — | 2025-11-12 00:00:00 | D |
| 4 | 100000 | 18000.0 | — | Conversion of Exercise of derivative security at price 0.18 per share. | RUSSELL ALAN J | Officer and Director | — | 2025-11-12 00:00:00 | D |
| 5 | 10700 | 199403.0 | — | Purchase at price 18.64 per share. | FOX JONATHAN C | Director | — | 2025-11-11 00:00:00 | D |
| 6 | 728 | — | — | Stock Award(Grant) at price 0.00 per share. | FOX JONATHAN C | Director | — | 2025-10-01 00:00:00 | D |
| 7 | 100000 | 1459760.0 | — | Sale at price 14.60 per share. | RUSSELL ALAN J | Officer and Director | — | 2025-08-26 00:00:00 | D |
| 8 | 100000 | 18000.0 | — | Conversion of Exercise of derivative security at price 0.18 per share. | RUSSELL ALAN J | Officer and Director | — | 2025-08-26 00:00:00 | D |
| 9 | 1428 | 19124.0 | — | Sale at price 13.39 per share. | CARRUTHERS ROBERT MICHAEL | Chief Financial Officer | — | 2025-08-12 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -189.14M | -156.54M | -112.62M | -71.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -167.79M | -133.81M | -100.16M | -67.64M |
| ReconciledDepreciation | 2.27M | 2.29M | 1.73M | 538.00K |
| EBITDA | -189.14M | -156.54M | -112.62M | -71.12M |
| EBIT | -191.41M | -158.83M | -114.36M | -71.66M |
| NetInterestIncome | 23.61M | 25.02M | 14.19M | 4.02M |
| InterestIncome | 23.61M | 25.02M | 14.19M | 4.02M |
| NormalizedIncome | -167.79M | -133.81M | -100.16M | -67.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -167.79M | -133.81M | -100.16M | -67.64M |
| TotalExpenses | 191.41M | 158.83M | 114.36M | 71.66M |
| TotalOperatingIncomeAsReported | -191.41M | -158.83M | -114.36M | -71.66M |
| DilutedAverageShares | 94.72M | 63.72M | 63.23M | 37.53M |
| BasicAverageShares | 94.72M | 63.72M | 63.23M | 37.53M |
| DilutedEPS | -0.42 | -1.57 | -0.31 | -1.14 |
| BasicEPS | -0.42 | -1.57 | -0.31 | -1.14 |
| DilutedNIAvailtoComStockholders | -167.79M | -133.81M | -100.16M | -67.64M |
| NetIncomeCommonStockholders | -167.79M | -133.81M | -100.16M | -67.64M |
| NetIncome | -167.79M | -133.81M | -100.16M | -67.64M |
| NetIncomeIncludingNoncontrollingInterests | -167.79M | -133.81M | -100.16M | -67.64M |
| NetIncomeContinuousOperations | -167.79M | -133.81M | -100.16M | -67.64M |
| PretaxIncome | -167.79M | -133.81M | -100.16M | -67.64M |
| NetNonOperatingInterestIncomeExpense | 23.61M | 25.02M | 14.19M | 4.02M |
| InterestIncomeNonOperating | 23.61M | 25.02M | 14.19M | 4.02M |
| OperatingIncome | -191.41M | -158.83M | -114.36M | -71.66M |
| OperatingExpense | 191.41M | 158.83M | 114.36M | 71.66M |
| ResearchAndDevelopment | 151.39M | 126.97M | 90.91M | 54.03M |
| SellingGeneralAndAdministration | 40.02M | 31.87M | 23.45M | 17.63M |
| GeneralAndAdministrativeExpense | 40.02M | 31.87M | 23.45M | 17.63M |
| OtherGandA | 40.02M | 31.87M | 23.45M | 17.63M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 106.25M | 94.84M | 70.45M | 63.26M |
| ShareIssued | 106.25M | 94.84M | 70.45M | 63.26M |
| TotalDebt | 3.99M | 4.74M | 5.41M | 4.41M |
| TangibleBookValue | 522.26M | 459.22M | 318.83M | 346.72M |
| InvestedCapital | 522.26M | 459.22M | 318.83M | 346.72M |
| WorkingCapital | 516.01M | 451.62M | 310.23M | 340.41M |
| NetTangibleAssets | 522.26M | 459.22M | 318.83M | 346.72M |
| CapitalLeaseObligations | 3.99M | 4.74M | 5.41M | 4.41M |
| CommonStockEquity | 522.26M | 459.22M | 318.83M | 346.72M |
| TotalCapitalization | 522.26M | 459.22M | 318.83M | 346.72M |
| TotalEquityGrossMinorityInterest | 522.26M | 459.22M | 318.83M | 346.72M |
| StockholdersEquity | 522.26M | 459.22M | 318.83M | 346.72M |
| GainsLossesNotAffectingRetainedEarnings | 677.00K | 420.00K | 99.00K | -1.35M |
| OtherEquityAdjustments | 677.00K | 420.00K | 99.00K | -1.35M |
| RetainedEarnings | -546.37M | -378.58M | -244.76M | -144.60M |
| AdditionalPaidInCapital | 1.07B | 837.36M | 563.49M | 492.67M |
| CapitalStock | 10.00K | 9.00K | 7.00K | 6.00K |
| CommonStock | 10.00K | 9.00K | 7.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 30.35M | 27.60M | 21.20M | 20.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.98M | 3.74M | 4.43M | 3.80M |
| OtherNonCurrentLiabilities | 329.00K | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 2.98M | 3.74M | 4.43M | 3.80M |
| LongTermCapitalLeaseObligation | 2.98M | 3.74M | 4.43M | 3.80M |
| CurrentLiabilities | 27.37M | 23.86M | 16.77M | 16.59M |
| CurrentDebtAndCapitalLeaseObligation | 1.01M | 996.00K | 980.00K | 608.00K |
| CurrentCapitalLeaseObligation | 1.01M | 996.00K | 980.00K | 608.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.43M | 10.06M | 5.70M | 4.03M |
| PayablesAndAccruedExpenses | 13.93M | 12.81M | 10.10M | 11.95M |
| CurrentAccruedExpenses | 7.92M | 7.23M | 6.07M | 5.84M |
| Payables | 6.01M | 5.58M | 4.03M | 6.11M |
| AccountsPayable | 6.01M | 5.58M | 4.03M | 6.11M |
| TotalAssets | 552.60M | 486.82M | 340.04M | 367.10M |
| TotalNonCurrentAssets | 9.22M | 11.33M | 13.04M | 10.10M |
| OtherNonCurrentAssets | 262.00K | 348.00K | 251.00K | 548.00K |
| NetPPE | 9.22M | 11.07M | 12.69M | 9.85M |
| AccumulatedDepreciation | -6.77M | -4.68M | -2.62M | -1.06M |
| GrossPPE | 15.99M | 15.76M | 15.31M | 10.92M |
| Leases | 9.65M | 9.65M | 8.73M | 0.00 |
| ConstructionInProgress | 77.00K | 0.00 | 80.00K | 7.34M |
| OtherProperties | 5.46M | 5.30M | 5.72M | 3.30M |
| MachineryFurnitureEquipment | 807.00K | 807.00K | 778.00K | 281.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 543.38M | 475.48M | 327.00M | 357.00M |
| OtherCurrentAssets | 13.28M | 5.31M | 8.60M | 5.05M |
| PrepaidAssets | 5.05M | 2.98M | ||
| CashCashEquivalentsAndShortTermInvestments | 530.11M | 470.17M | 318.39M | 351.95M |
| OtherShortTermInvestments | 468.96M | 428.50M | 232.30M | 329.95M |
| CashAndCashEquivalents | 61.15M | 41.67M | 86.10M | 21.99M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -144.07M | -110.34M | -97.69M | -58.18M |
| IssuanceOfCapitalStock | 187.36M | 239.15M | 52.62M | 129.16M |
| CapitalExpenditure | -256.00K | -1.31M | -5.75M | -5.55M |
| EndCashPosition | 61.15M | 41.67M | 86.10M | 21.99M |
| BeginningCashPosition | 41.67M | 86.10M | 21.99M | 15.57M |
| ChangesInCash | 19.48M | -44.43M | 64.10M | 6.43M |
| FinancingCashFlow | 196.09M | 249.25M | 53.17M | 129.64M |
| CashFlowFromContinuingFinancingActivities | 196.09M | 249.25M | 53.17M | 129.64M |
| NetOtherFinancingCharges | -262.00K | -165.00K | -251.00K | -124.00K |
| ProceedsFromStockOptionExercised | 8.73M | 10.37M | 713.00K | 725.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 187.36M | 239.15M | 52.62M | 129.16M |
| CommonStockIssuance | 187.36M | 239.15M | 52.62M | 129.16M |
| InvestingCashFlow | -32.79M | -184.66M | 102.89M | -70.58M |
| CashFlowFromContinuingInvestingActivities | -32.79M | -184.66M | 102.89M | -70.58M |
| NetInvestmentPurchaseAndSale | -32.53M | -183.34M | 108.63M | -65.03M |
| SaleOfInvestment | 494.69M | 293.71M | 364.50M | 227.36M |
| PurchaseOfInvestment | -527.23M | -477.06M | -255.87M | -292.39M |
| NetPPEPurchaseAndSale | -256.00K | -1.31M | -5.75M | -5.55M |
| PurchaseOfPPE | -256.00K | -1.31M | -5.75M | -5.55M |
| OperatingCashFlow | -143.82M | -109.03M | -91.95M | -52.63M |
| CashFlowFromContinuingOperatingActivities | -143.82M | -109.03M | -91.95M | -52.63M |
| ChangeInWorkingCapital | -5.37M | 10.33M | -1.56M | 4.09M |
| ChangeInOtherWorkingCapital | 1.24M | 1.62M | ||
| ChangeInOtherCurrentLiabilities | -748.00K | -220.00K | -104.00K | 2.92M |
| ChangeInPayablesAndAccruedExpense | 3.34M | 7.26M | 2.10M | 2.62M |
| ChangeInAccruedExpense | 3.06M | 5.52M | 2.19M | 2.57M |
| ChangeInPayable | 272.00K | 1.74M | -92.00K | 47.00K |
| ChangeInAccountPayable | 272.00K | 1.74M | -92.00K | 47.00K |
| ChangeInPrepaidAssets | -7.96M | 3.29M | -3.55M | -1.45M |
| StockBasedCompensation | 34.75M | 24.71M | 17.56M | 10.92M |
| AmortizationOfSecurities | -7.67M | -12.54M | -9.52M | -543.00K |
| DepreciationAmortizationDepletion | 2.27M | 2.29M | 1.73M | 538.00K |
| DepreciationAndAmortization | 2.27M | 2.29M | 1.73M | 538.00K |
| Depreciation | 2.27M | 2.29M | 1.73M | 538.00K |
| NetIncomeFromContinuingOperations | -167.79M | -133.81M | -100.16M | -67.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EWTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|